Daiichinkyo Co (STU:D4S) Institutional Ownership : 47.02% (As of May. 14, 2024)

View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Daiichinkyo Co's institutional ownership is 47.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Daiichinkyo Co's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Daiichinkyo Co's Float Percentage Of Total Shares Outstanding is 0.00%.

Daiichinkyo Co Institutional Ownership Historical Data

The historical data trend for Daiichinkyo Co's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Institutional Ownership Chart

Daiichinkyo Co Historical Data

The historical data trend for Daiichinkyo Co can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	46.84	46.83	46.87	47.19	47.17	47.31	46.82	47.15	47.40	47.02

Daiichinkyo Co Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Daiichinkyo Co (STU:D4S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (STU:D4S) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

DSNKY:USA DSKYF:USA 4568:Japan

Address

3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426

Website

https://www.daiichisankyo.com

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co (STU:D4S) Headlines

No Headlines